Orphenadrine Citrate

枸橼酸奥芬那君

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameOrphenadrine Citrate
Drug Alias Nameorphenadrine dihydrogen citrate枸橼酸邻甲苯海拉明柠檬酸邻甲苯海拉明Norflex
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHistamine H1 receptor antagonistsGlutamate [NMDA] receptor antagonists
TargetsHistamine H1 receptorGlutamate [NMDA] receptor
Therapy Area/IndicationsPainMusculoskeletal PainMuscle Spasticity
Global Approved IndicationsPainMuscle Spasticity
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date1959/11/14
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusWithdrawn
Highest Status in ChinaN/A
Originator CompaniesBausch Health Companies Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBausch & LombPharmaceutical Associates Inc
Active IndicationsN/A
Inactive IndicationsPainMusculoskeletal PainMuscle Spasticity

Other Information

ATC CodeM03BC01
Related LinksWikipediaDrugBankKEGG